Wechselwirkungen · Tafinlar
Tafinlar 50 mg hard capsules Tafinlar 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-218706 · Präparat HOS-216245
Dabrafenib is an enzyme inducer and increases the synthesis of drug-metabolising enzymes including CYP3A4, CYP2Cs and CYP2B6 and may increase the synthesis of transporters. This results in reduced plasma levels of medicinal products metabolised by these enzymes and may affect some transported medicinal products. The reduction in plasma concentrations can lead to lost or reduced clinical effect of these medicinal products. There is also a risk of increased formation of active metabolites of these medicinal products. Enzymes that may be induced include CYP3A in the liver and gut, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and UGTs (glucuronide conjugating enzymes). The transport protein P-gp may also be induced as well as other transporters, e.g. MRP-2. Induction of OATP1B1/1B3 and BCRP is not likely based on the observations from a clinical study with rosuvastatin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-19T17:15:00Z · SHA-256 9031057737e69f93f06bd97c0cab21f19ae76210a1d3e52f9c8020131fd58e8a · Passage fc30313210fbbf04027ec99d0d91497b01969d89c693cb57b89beb15c9cf5767 · Zeichen 2610–3476 im Abschnitt